James J. Kobie

This study shows that mice vaccinated with a single-cycle influenza virus or a neuraminidase-decorated nanoparticle are protected from lethal H5N1 influenza challenge.

This paper develops a bireporter recombinant SARS-CoV-2 Omicron BA.5 strain for tracking viral infections and testing antivirals and neutralizing antibodies in vitro and in vivo.

This study shows that a combination of antibodies targeting both the SARS-CoV-2 spike protein's receptor binding domain (RBD) and stem helix (SH) domains prevents the emergence of viral escape mutants.

This paper develops recombinant influenza A viruses expressing nanoluciferase for in vitro and in vivo tracking of viral infections, showing they replicate efficiently and can be imaged using IVIS.

This study characterizes a broad-neutralizing influenza antibody, 1122A11, showing it neutralizes multiple NA subtypes and adapts to recent glycosylation changes in H3N2 viruses.

The paper benchmarks 49 algorithms for predicting B. pertussis vaccination outcomes, finding that purpose-built models outperform literature-based ones due to better handling of nonlinearities and data preprocessing.

This study develops a monoclonal antibody that broadly neutralizes multiple SARS-CoV-2 variants, including JN.1, and shows its protective efficacy in mice.